# AVC-203

Source: https://onco.cc/drugs/avc-203/  
OnCo record `avc-203` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AVC-203 is an experimental allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy from AvenCell Therapeutics, in phase 1 trials for relapsed/refractory B-cell malignancies and diffuse large B-cell lymphoma.

## Summary

AVC-203 (Allo-QuadCAR01-T) is an allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy from AvenCell Therapeutics, with AvenCell Europe GmbH as partner. Off-the-shelf donor CAR-T cells, CRISPR-engineered, that target cells expressing CD19 and/or CD20, built on the switchable RevCAR receptor so other targets can be added through bridging proteins. Its furthest stage is phase 1, for relapsed/refractory B-cell malignancies and diffuse large B-cell lymphoma. No clinical trial naming it is registered on ClinicalTrials.gov. First patient dosed in phase 1 QUADvance in April 2026 (company release 2 April 2026); registry phase 1/2 recruiting (NCT07284433). It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: Allo-QuadCAR01-T
- Tags: pipeline
- Code: AVC-203
- Modality: Allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy
- Mechanism: Off-the-shelf donor CAR-T cells, CRISPR-engineered, that target cells expressing CD19 and/or CD20, built on the switchable RevCAR receptor so other targets can be added through bridging proteins.

## Sources

- AvenCell Therapeutics: avencell.com: https://avencell.com/avencell-therapeutics-announces-first-patient-dosed-in-phase-i-quadvance-study-with-avc-203-a-novel-allogeneic-cd19-cd20-dual-targeting-car-t-investigational-therapy-for-the-treatment-of-relapsed-ref/
- AvenCell Therapeutics: avencell.com: https://avencell.com/pipeline/
- AvenCell Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07284433

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- companies: [AvenCell Therapeutics](https://onco.cc/companies/avencell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/avc-203.json